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Oral prednisolone for acute otitis media in
children: a pilot, pragmatic, randomised,
open-label, controlled study (OPAL study)
Respati W. Ranakusuma1,2* , Amanda R. McCullough1, Eka D. Safitri2, Yupitri Pitoyo2, Widyaningsih Widyaningsih2,
Christopher B. Del Mar1 and Elaine M. Beller1
Abstract
Background: Acute otitis media (AOM) is associated with high antibiotic prescribing rates. Antibiotics are
somewhat effective in improving pain and middle ear effusion (MEE); however, they have unfavourable effects.
Alternative treatments, such as corticosteroids as anti-inflammatory agents, are needed. Evidence for the efficacy of
these remains inconclusive. We conducted a pilot study to test feasibility of a proposed large-scale randomised
controlled trial (RCT) to assess the efficacy of corticosteroids for AOM.
Methods: We conducted a pilot, pragmatic, parallel, open-label RCT of oral corticosteroids for paediatric AOM in
primary and secondary/tertiary care centres in Indonesia. Children aged 6 months–12 years with AOM were
randomised to either prednisolone or control (1:1). Physicians were blinded to allocation. Our objectives were to
test the feasibility of our full RCT procedures and design, and assess the mechanistic effect of corticosteroids, using
tympanometry, in suppressing middle ear inflammation by reducing MEE.
Results: We screened 512 children; 62 (38%) of 161 eligible children were randomised and 60 were analysed for
the primary clinical outcome. All study procedures were completed successfully by healthcare personnel and
parents/caregivers, despite time constraints and high workload. All eligible, consenting children were appropriately
randomised. One child did not take the medication and four received additional oral corticosteroids. Our revised
sample size calculation verified 444 children are needed for the full RCT. Oral corticosteroids did not have any
discernible effects on MEE resolution and duration. There was no correlation between pain or other symptoms and
MEE change. However, prednisolone may reduce pain intensity at day 3 (Visual Analogue Scale mean difference −
7.4 mm, 95% confidence interval (CI) − 13.4 to − 1.3, p = 0.018), but cause drowsiness (relative risk (RR) 1.8, 95% CI
1.1 to 2.8, p = 0.016). Tympanometry curves at day 7 may be improved (RR 1.8, 95% CI 1.0 to 2.9). We cannot yet
confirm these as effects of corticosteroids due to insufficient sample size in this pilot study.
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© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: respati.wulansari@rscm.co.id
1Institute for Evidence-Based Healthcare, Bond University, 14 University Drive,
Robina, QLD 4226, Australia
2Clinical Epidemiology and Evidence-Based Medicine Unit, Dr. Cipto
Mangunkusumo General Hospital – Faculty of Medicine Universitas
Indonesia, Diponegoro 71, Jakarta 10430, Indonesia
Ranakusuma et al. Pilot and Feasibility Studies           (2020) 6:121 
https://doi.org/10.1186/s40814-020-00671-5
(Continued from previous page)
Conclusions: It is feasible to conduct a large, pragmatic RCT of corticosteroids for paediatric AOM in Indonesia.
Although oral corticosteroids may reduce pain and improve tympanometry curves, it requires an adequately
powered clinical trial to confirm this.
Trial registration: Study registry number: ACTRN12618000049279. Name of registry: the Australian New Zealand
Clinical Trials Registry (ANZCTR). Date of registration: 16 January 2018.
Keywords: Otitis media, Acute disease, Anti-bacterial agents, Glucocorticoids, Corticosteroids, Middle ear effusion,
Pilot projects, Acoustic impedance tests
Background
Antibiotic resistance is a global health threat, largely be-
cause of antibiotic use [1–3]. Use of antibiotics is also
associated with unfavourable effects (e.g. vomiting, diar-
rhoea) [4]. There is a particularly high rate of antibiotic
prescribing for acute respiratory infections (ARIs) in
outpatient settings (primary and secondary care): 50% in
the USA; 53% in European countries; 34% in Malaysia;
and up to 78% in Indonesia [5–8].
Acute otitis media (AOM), a middle ear inflammation,
is an ARI that is commonly found in children, particu-
larly before the age of five [9, 10]. Antibiotics are com-
monly prescribed. A Cochrane review showed that
antibiotics are effective in improving acute pain and
tympanometry results, as well as other clinical outcomes
(e.g. tympanic membrane perforation, contralateral
AOM). However, due to their modest benefits along
with significant potential for unfavourable effects, antibi-
otics are not mandatory treatment for AOM, particularly
for mild AOM. Therefore, it is important to emphasize
both benefits and harm of antibiotic use to the patients
and their parents and involve them in treatment decision
making in the management of AOM.
In Australia, 89% of new AOM cases were managed by
antibiotics between 2010 and 2015 [11]. In Indonesia,
our feasibility survey showed that up to 88% of physi-
cians would prescribe antibiotics for mild AOM, al-
though antibiotics are most beneficial for severe AOM
(i.e. severe symptoms, young children with bilateral
AOM, tympanic membrane perforation) [9]. These rates
are higher compared to other western countries such as
the USA (57.6%), Iceland (70.4%), Denmark (73.7%) and
Sweden (86.7%) [12–14]. This condition may be affected
by two contradictory Indonesian practice guidelines for
AOM [15, 16]. The AOM guideline for primary care
practitioners recommends the use of antibiotics for both
mild and severe AOM. The only difference is the anti-
biotic dose, which recommends a higher dose for severe
AOM [15]. On the other hand, the guideline for Ear,
Nose and Throat (ENT) specialists recommends anti-
biotic use for only severe AOM, although it does not
specifically describe the definition of severe AOM [16].
In addition, despite of the existence of national regulation
on antibiotic use, its implementation is less enforced in
Indonesia and leads to antibiotic self-medication [17, 18].
High rates of antibiotic use, despite of its modest ben-
efits and side effects and antibiotic resistance, indicate
the necessity to find effective alternative treatments for
AOM (e.g. decongestants, herbal preparations, cortico-
steroids) [19–21]. The existing alternative treatments
have insufficient evidence to be recommended in clinical
practice [19–21]. Since inflammation is a key mechanism
of AOM, corticosteroids are a potential treatment. Al-
though they have been effectively used for other ARIs
(e.g. pneumonia, bacterial meningitis) [22, 23], their ef-
fect on AOM remains unclear [24, 25]. Aside from po-
tential beneficial effects on inflammation, corticosteroids
also may cause side effects. Gastrointestinal disturbances
and behavioural changes have been identified as com-
mon side effects [26]. Although short-term use of a cor-
ticosteroid is unlikely to induce serious harm, one
systematic review reported 1% of children experienced
increased susceptibility to infections due to the immuno-
suppression effect of corticosteroids [26].
Our Cochrane review shows that systemic corticosteroids
may be effective in improving clinical symptoms of AOM
[24]. However, this was based on one small study demon-
strating uncertain effects of systemic corticosteroids for
AOM due to a wide confidence interval that included both
benefits and harm. High-quality evidence is crucial to ad-
dress uncertainties around the effects of corticosteroids for
AOM. Therefore, we plan to conduct an adequately pow-
ered clinical trial to assess both benefits and harm of corti-
costeroids for children with AOM. Our original sample size
calculation demonstrated that we need 760 children to be
able to detect actual effects of oral corticosteroids for chil-
dren with AOM. Prior to this, we conducted a pilot study
to test the feasibility of characteristics of our full RCT de-
sign and procedures in 60 children, including a mechanistic
sub-study using tympanometry (tympanometry sub-study)
to study the effect of corticosteroids on middle ear effusion
(MEE). The clinical findings from this study, although they
cannot be definitive due to a small sample size, can indicate
the direction of potential clinical effects of oral corticoste-
roids for AOM, which can then be confirmed in an ad-
equately powered clinical trial.
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Methods
Study aims and objectives
This pilot study aimed to test all pre-specified methods
and procedures that are planned to be implemented in
the full RCT, but in a smaller sized study.
The objectives for the pilot study were to assess the
feasibility of characteristics of the full RCT design and
procedures (e.g. recruitment, randomisation, outcome
measurement, experience and obstacles of physicians and
parents/caregivers, sample size verification) and assess the
mechanistic effect of corticosteroids in suppressing in-
flammation in the middle ear specifically by reducing
MEE.
Prior to our study implementation, our study protocol
was reviewed and approved by the Ethics Committee
Faculty of Medicine Universitas Indonesia and the Bond
University Human Research Ethics Committee (BUH-
REC) Australia (see Declarations section).
Study design and setting
This was a pilot parallel, pragmatic, stratified, randomised,
open-label, single-blind, controlled study in an allocation
ratio of 1:1. We planned to conduct this study in seven
hospitals in Jakarta and Bekasi as described in our proto-
col [27]; however, we only received research permits from
six hospitals. Due to low rate of recruitment, we added
two primary care centres in Jakarta to the study.
Participants
Inclusion criteria
We included children aged 6 months to 12 years old
with AOM, defined as current onset (within 48 h) of
AOM-relevant symptoms (e.g. earache, ear tugging/rub-
bing or irritability in non-verbal children). Otoscopic
findings of acute inflammation (e.g. erythema) and mid-
dle ear effusion (e.g. bulging, air-fluid level) confirmed
the diagnosis.
Exclusion criteria
We excluded children (1) with major and severe medical
conditions (e.g. heart diseases, tuberculosis), (2) who
were immunocompromised (e.g. HIV infection, under
cancer treatment), (3) with congenital malformations
and/or syndromes (e.g. cleft palate, Down syndrome), (4)
with high risk of strongyloidiasis infections, (5) with ear
ventilation tube(s), (6) who had been exposed to persons
with varicella or active Zoster infection in the preceding
3 weeks without prior varicella immunisation or in-
fection, (7) who had taken systemic (oral, injection)
or topical steroids in the preceding 4 weeks, (8) who
had taken antibiotics in the preceding 2 weeks and
(9) who were hypersensitive to prednisolone or pred-
nisone, or other corticosteroids. Further details of the
recruitment process including obtaining consent are
in our protocol [27].
Study intervention arm
We gave prednisolone tablets (Lupred®5) at a daily dose
of 1–2 mg/kg of body weight for 5 days, which was oper-
ationalised based on age: 10 mg/day for children aged 6
months to up to 2 years; 20 mg/day for children aged 2
up to 6 years; and 30 mg/day for children aged 6 to 12
years [28]. We provided liquid sweetener to make pred-
nisolone more palatable. Children with mild AOM who
were randomised to the intervention arm received pred-
nisolone plus expectant observation, whilst those with
severe AOM received prednisolone plus antibiotics (see
Fig. 1). Further details of administration and timing of
study medication are described in our protocol [27].
Control arm
Children with mild AOM who were randomised to the
control arm received expectant observation alone, whilst
those with severe AOM received antibiotics alone (see
Fig. 1).
Concurrent treatment
Physicians were able to prescribe medications for symp-
toms (e.g. analgesic, decongestant) as per their usual
practice. The physicians were not able to prescribe oral
corticosteroids.
Outcomes
For the first objective of assessing the feasibility of charac-
teristics of our full RCT design and procedures, we mea-
sured six outcomes: (1) recruitment rates; (2) successful
completion of the study procedures; (3) successful meas-
urement of planned outcomes; (4) the experiences and
barriers of participating healthcare personnel (i.e. physi-
cians, nurses, audiologists, pharmacists) and parents/care-
givers in measuring planned outcomes; (5) adherence to
study visits and study medication; and (6) verification of
the sample size calculation for the full RCT using pain
measures in the control group.
For the second objective of assessing the mechanistic
effect of corticosteroids in suppressing inflammation in
the middle ear, we measured three outcomes: (a) change
in MEE at various time points; (b) duration of MEE; and
(c) correlation between ear pain and other symptoms
with the changes in MEE at various time points.
Recruitment rate was defined as the proportion of
consultations with potentially eligible children who pro-
vided their consent to be included in the study. We
assessed this outcome monthly using a logbook com-
pleted by participating nurses and physicians.
The successful completion of the study procedures
and outcome measures was defined as the proportion of
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participating healthcare personnel and parents/care-
givers who were able to conduct study procedures and
measure outcomes in order to obtain valid results. The
study procedures were (1) obtaining consent; (2) recruit-
ment and stratification; (3) otoscopic assessment; (4)
pain measures using Visual Analogue Scale (VAS) and
Acute Otitis Media Severity of Symptoms (AOM-SOS)
scale; (5) randomisation, treatment allocation and pre-
scription dispensing; (6) preparation, completion, com-
pilation and storage of case report forms (CRFs); (7)
tympanometry examination and interpretation; (8)
preparation and dispensing of study medication; and (9)
completion of the symptom diary. These outcomes were
measured using the logbook, case report form and the
symptom diary (Additional file 1. Case report forms).
For the assessment of the experience and barriers to
measuring outcomes, we used a feedback form (see
Additional file 1. Case report forms). Each question
represented a study procedure and had five responses
(‘very easy’, ‘easy’, ‘neutral’, ‘difficult’ and ‘very diffi-
cult’). We asked the healthcare personnel and parents
to choose one response. We asked those who chose
Fig. 1 Flowchart of the study stratification and randomisation
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‘difficult’ to choose obstacle(s) describing their experi-
ence during that procedure or measurement. They
could choose more than one option or write their per-
sonal experience.
We assessed the adherence to study medication by
identifying the proportion of children who took the
study medication (prednisolone) for 5 days per protocol
divided by all children in the prednisolone group. This
outcome was measured using the symptom diary. The
adherence to the study visit was assessed by identifying
the proportion of children who came to follow-up visits
at day 3, day 7, day 30, and day 90 per protocol divided
by all children randomised to the study. This outcome
was measured using the follow-up card, the consent
form and the symptom diary.
The verification of sample size for the full RCT was
calculated by identifying the proportion of children with
mild and severe AOM in the pilot study with ongoing
pain represented as VAS score ≥ 5 mm, at day 3, in the
control group.
We assessed change in MEE at day 3, day 7, day 30
and day 90 by measuring static acoustic admittance
(SAA), which is defined as ‘the amount of energy
absorbed by the tympanic membrane and middle ear’.
We assumed that a difference of 0.3 mmho was a mini-
mum clinically important one for SAA [29].
For duration of MEE, we only conducted tympanome-
try at follow-up visits. We were not able to identify
whether the effusion had persisted, disappeared or reap-
peared between these visits. Therefore, we reported this
as the proportion of children who had a complete reso-
lution of MEE which is represented by a type A curve at
follow-up visits. We used the modification of Jerger to
classify the tympanogram curve types, as follows: (1) a
type A curve indicating a normal middle ear; (2) type C
curves including a C1 curve, which indicates a transition
from a normal middle ear to an early MEE, and a C2
curve representing an early MEE; and (3) a type B curve,
strongly indicating the presence of MEE or a definite
MEE [30–33].
We assessed the correlation between ear pain and
other symptoms (i.e. ear tugging, irritability, crying, lack
of sleep, lack of appetite, loss of playfulness, fever) using
VAS and AOM-SOS assessed by parents in the symptom
diary with the changes in SAA at day 3, day 7, day 30
and day 90.
The planned primary outcome of the full RCT is the
proportion of children with pain that has not reduced by
the minimum clinically important amount (10 mm VAS)
by day 3 [34, 35]. The secondary outcomes are (1) the
proportion of children with ongoing pain (VAS ≥ 5 mm)
[36] at day 1, day 3, day 5, day 7 and day 14; (2) reduc-
tion of pain intensity measured using VAS at similar
time points; (3) reduction of overall symptoms measured
using AOM-SOS at similar time points [37]; (4) reduc-
tion of overall pain duration; (5) complications related to
AOM; (6) the proportion of children with mild AOM re-
quiring antibiotics and those with severe AOM requiring
second-line antibiotics; (7) AOM recurrence; (8) adverse
effects; and (9) the adherence to study medication. For
the VAS and AOM-SOS assessment, we used data from
the symptom diary completed by the parents. As this is
a pilot, we do not report here the primary outcome of
the full RCT. However, we do report the first secondary
outcome. Further details of data collection for the pilot
and full RCT are described in our protocol paper [27].
Sample size
We did not formally determine the sample size for this
pilot study. We included 60 children with AOM in our
pilot study based on sample size calculation for the
tympanometry sub-study [27]. Our feasibility survey
demonstrated that it would require 9 months including
3-month follow-up to recruit 60 children. We did not
conduct an interim analysis due to the small sample size
and short study duration.
Recruitment and stratification
For the full RCT, we plan to stratify children by clinical
specialty or healthcare centre level (primary care or sec-
ondary/tertiary healthcare centres) and severity of AOM
(mild or severe). As we intended to only include ENT
specialists who worked at secondary/tertiary centres in
this pilot study, we stratified children based only on
AOM severity. Details on stratification criteria are in the
protocol paper [27].
To help the recruitment and stratification process, in-
cluding randomisation and tympanometry examination
where necessary, we recruited and trained seven research
assistants, including one administrative assistant, to sup-
port the implementation of the study (RO, DN, IG, RA,
RS, FR, VV).
Randomisation and allocation concealment
After confirmation of eligibility, and completion of the
clinical examination, but prior to randomisation, physi-
cians dispensed two prescriptions to the nurse. The first
prescription was for general AOM medications (e.g. an-
tibiotics, decongestants). The second one was for the
study medication. The nurse then only dispensed the
second prescription to patients who were randomised to
the intervention arm. Further details of randomisation
process, including the preparation, dispensing and cen-
tral storage of study medication are in the protocol
paper [27].
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Blinding
The appointed nurses and patients or parents/caregivers
were aware of the intervention allocation. The physicians
and audiologists were blinded to the allocation [27]. At
the primary care centre, the principal investigator (RR)
and research assistants (RO, DN, IG, RA, RS, FR) con-
ducted randomisation and tympanometry examination
because of the limited availability of healthcare
personnel for the study. Therefore, it was not possible to
conceal allocation after randomisation. However, the re-
search assistants were not involved in the treatment de-
cisions and ensured the clinician was not aware of the
intervention allocation.
Statistical methods
We report the outcomes of the pilot study (e.g. recruit-
ment rate, the success and ability of study procedures
and measures, adherence to study visits and medication)
as proportions in percentages (n, %).
For the verification of sample size calculation, we used
the proportion of the children in both mild and severe
groups, and pain measures among the controls to update
our calculation of failure rate of ongoing pain at day 3.
We did not change the assumed relative of risk on on-
going pain at day 3, as the pilot results arise from a small
sample.
For the clinical outcomes, since it was a pilot study
and we did not want to reveal the result of the primary
outcome of the proposed full RCT, we only report the
proportion of children with ongoing pain (binary out-
come) and reduction of pain and other symptom severity
(continuous outcome) at day 1, day 3, day 5, day 7 and
day 14. For clinical and tympanometry continuous out-
comes (i.e. pain and symptoms scores measured by VAS
and AOM-SOS, SAA value), we conducted linear regres-
sion to determine the unadjusted and adjusted mean dif-
ference (MD), 95% confidence interval (CI) and the p
values for the comparison between groups at day 3 as a
primary time point . The adjusted MD used the baseline
result (equivalent to ANCOVA). Spearman’s correlation
coefficient was calculated to determine the correlation
between ear pain using VAS and SAA values on the af-
fected ear for unilateral AOM and the worst ear for bi-
lateral AOM, as well as between other relevant
symptoms using AOM-SOS and the similar SAA values.
We used STATA 15.1 software for statistical analysis.
For clinical and tympanometry binary outcomes (i.e.
the proportion of children with persisting pain of VAS
≥ 5 mm and those who had complete MEE resolution at
various time points), we conducted chi-squared tests
and reported relative risk (RR) and 95% CI for the com-
parison between groups. We presented the p values of
the outcomes measured at day 3 (primary time point).
We used Fisher’s exact test to determine statistically
significant differences in effect estimates of binary out-
comes between the prednisolone and control group
where there were small event numbers (< 10 per variable
cell).
For time to pain resolution, we identified the time
point where children had resolution of pain (VAS < 5
mm) and presented these as a median, and then com-
pared the median between the two groups using a
Wilcoxon rank sum test.
Results
Recruitment
We screened 512 children with ear pain (22 February–
30 November 2018) and 161 children (31%) were
assessed using the eligibility criteria (see Fig. 2). All phy-
sicians were able to confirm AOM using an otoscope.
Sixty-two (38%) eligible children were stratified to mild
and severe AOM. Thirty-one children were randomly al-
located to the prednisolone group (8 mild and 23 severe
AOM) and 31 children to the control group (7 mild and
24 severe AOM). Two children left the study before data
collection at day 3 resulting in 60 children (29 prednisol-
one versus 31 control group) being analysed for the
planned primary outcome of the full RCT. The study
was ended on February 2019 allowing for the 3-month
follow-up of the last patient.
Baseline data
The baseline characteristics between the two groups
were similar in gender and had an age range of 61 to 73
months (see Table 1). There were more children in the
control group whose parents had a low education level
(primary and secondary education), were exposed to par-
ental smoking (passive smoking) or received amoxicillin
and amoxicillin/clavulanate and acetaminophen at base-
line. Children in the prednisolone group were more
likely to receive cefixime. Forty-seven percent of the
children were found to have hyperaemic tympanic mem-
brane only on the otoscopic examination.
Numbers analysed
For the primary outcomes of the full RCT, we analysed
60 children at day 3. For the secondary outcomes, we
analysed 58 children (29 prednisolone versus 29 control
group) as two more children left the study after data col-
lection at day 3. For the tympanometry sub-study, we
conducted tympanometry examinations on 58 children
(93%) and analysed 37 children (15 prednisolone versus
22 control group) who had sufficient tympanometry
findings at both baseline and day 3. We were not able to
fulfil the sample size to 60 children due to difficulty in
recruitment and budget constraints which prevented the
extension of the recruitment period.
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Fig. 2 Study flowchart
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Table 1 Baseline and clinical characteristics of randomised children by treatment group
Characteristics Prednisolone (n = 31) Control (n = 31)
Baseline characteristics
Age (months) mean ± SD 60. 7 ± 32.2 73.2 ± 38.3
Sex—male (n; %) 15 (48) 18 (58)
Breastfeeding (n; %) 28 (90) 27 (87)
Breastfeeding until at least the first 6 months of life (n; %) 20 (71) 19 (70)
Child day care attendance (n; %) 1 (3) 1 (3)
Duration per week (h) mean ± SD 50 35
Pre-school or school attendance (n; %) 21 (68) 20 (64)
Duration per week (hours) mean ± SD 4.9 ± 2.0 4.7 ± 2.0
Parental education (father)a
Primary education (i.e. elementary school) 1 (3) 2 (6)
Secondary education (i.e. middle and high school) 13 (42) 17 (55)
Tertiary education (e.g. diploma, bachelor, masters) 16 (52) 11 (35)
Parental education (mother)a
Primary education (i.e. elementary school) 0 (0) 2 (6)
Secondary education (i.e. middle and high school) 12 (39) 17 (55)
Tertiary education (e.g. diploma, bachelor, masters) 19 (61) 11 (35)
Pneumococcal vaccinations (n; %) 9 (29) 7 (23)
Influenzae vaccinations (n; %) 6 (19) 7 (23)
≥ 3 episodes of acute respiratory infections in the past year (n; %) 23 (74) 22 (71)
First episode of AOM 20 (64) 21 (68)
First episode of AOM at ≤ 2 years of age (n; %) 8 (26) 3 (10)
≥ 3 episodes of ear infection in the past year (n; %) 3 (10) 2 (6)
> 3 children in one house (n; %) 0 (0) 0 (0)
Passive smoking (n; %) 14 (45) 20 (64)
Ear discharge (n; %) 11 (35) 8 (26)
Concomitant diseases (n; %)
Allergic rhinitis 3 (10) 2 (6)
Bronchial asthma 0 (0) 1 (3)
History of atopy in the family 12 (39) 9 (29)
AOM lateralisation—unilateral (n; %) 20 (64) 18 (58)
Clinical characteristics
Common cold 27 (87) 28 (90)
Nose abnormalities (e.g. oedema, discharge) 23 (85) 23 (82)
Tonsil abnormalities (e.g. hyperaemic, oedema) 15 (55) 15 (53)
Throat abnormalities (e.g. hyperaemic, oedema) 15 (55) 8 (28)
Diagnosis of AOM
Confirmed by otoscope
Hyperaemic tympanic membrane only 12 (39) 17 (55)
Hyperaemic tympanic membrane and other signs of inflammation/middle ear effusionb 23 (74) 21 (68)
Confirmed by otoscope and clarified by tympanometryc 25 (86) 25 (86)
Initial antibiotic given (n; %)
Amoxicillin 4 (13) 11 (35)
Amoxicillin/clavulanate 5 (16) 8 (26)
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Outcomes and estimation
Recruitment rate
We collected logbooks from each study site to measure
the recruitment rate. However, most nurses did not
complete the logbook appropriately. The average recruit-
ment rate was 38.5% of potentially eligible children (see
Table 2). The main reasons for exclusion were (a) onset
> 2 days (24%); (b) lack of interest or reluctance of par-
ents to participate (14%); and (c) prior intake of antibi-
otics/steroids (10%). Three sites did not contribute to
patient recruitment because of no eligible cases. Only
one private hospital contributed to the study recruit-
ment. Therefore, we added two primary care centres to
the study.
The successful completion of the study procedures and
outcome measures
Prior to the study, we provided training to 66 physicians
(i.e. ENT specialists, GPs, paediatricians), 39 nurses, 35
pharmacists and 6 audiologists. During the training, we
coached and assisted them in conducting all study pro-
cedures and measures per protocol.
Twenty-three of 85 parents/caregivers of eligible
children (27%) declined to participate in the study
(see Table 2). All physicians (100%) successfully re-
cruited and stratified eligible children based on their
AOM severity, performed an otoscopic assessment
and measured pain and other relevant symptoms
using VAS and AOM-SOS, and reported the findings
as self-reporting assessment in the CRF. All eligible
children were successfully randomised and allocated
to their randomised intervention by nurses/research
assistants. All patients had the study medication pre-
scriptions dispensed as per protocol. All nurses were
able to appropriately prepare, compile and store the
CRF. All audiologists successfully performed tympano-
metry examination. However, there were incomplete
values caused by lack of sensitivity of tympanometry.
Table 1 Baseline and clinical characteristics of randomised children by treatment group (Continued)
Characteristics Prednisolone (n = 31) Control (n = 31)
Cefixime 12 (39) 3 (10)
Cefadroxil 1 (3) 1 (3)
Trimethoprim/sulfamethoxazole 0 (0) 1 (3)
Clarithromycin 1 (3) 0 (0)
Other treatment given by doctors at initial visit (n; %)
Acetaminophen 9 (29) 16 (52)
Nonsteroidal anti-inflammatory drugs 4 (13) 5 (16)
Decongestants and/or antihistamine 26 (84) 22 (71)
Cough medicine 18 (58) 14 (45)
Antibiotic ear drops 9 (29) 6 (19)
Nasal (topical) decongestant 6 (19) 2 (6)
Nasal corticosteroid 0 (0) 1 (3)
Vitamins or herbals 3 (10) 8 (26)
Ear diathermy 0 (0) 1 (3)
Inhalation 0 (0) 1 (3)
Others (e.g. mefenamic acid, nasal douching) 3 (10) 5 (16)
Tympanometry test (n; %) 29 (93) 29 (93)
Complete 15 (52) 18 (62)
Partial completion 0 (0) 6 (21)
Sufficient values for analysis 15 (52) 22 (76)
Type A 4 (27) 6 (27)
Type C1 2 (13) 4 (18)
Type C2 1 (7) 1 (4)
Type B (or flat) 8 (53) 11 (50)
aWe could not obtain the information of father’s (n = 2) and the mother’s education level (n = 1)
bA child with bilateral AOM may have two different otoscopic results (e.g. hyperaemic tympanic membrane only and hyperaemic tympanic membrane with other
signs of inflammation/middle ear effusion)
cFour patients did not undergo tympanometry examination due to severe pain, not recommended by physicians due severe bulging, uncooperative child and
nurse forgot. Patients with tympanic membrane perforation were considered as confirmed by otoscope and tympanometry
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One of 31 study medication packages (3%) was not
dispensed by the pharmacist, which had to be home
delivered by the researcher (RR).
One hundred percent of symptom diary data was
completed for analysis. However, only 60% of parents/
caregivers were able to complete the symptom diary
per protocol, which required us to collect data and
clarify unclear responses by interviewing 25 parents
retrospectively (see Table 3). We regularly checked
the completion of the symptom diary of day 0 to 3 at
the first follow-up visit (day 3) and day 4 to 7 at the
second visit (day 7), and after the diary collection at
day 14. We expected this strategy may reduce recall
bias. We interviewed the parents directly during the
consultation at the follow-up visits and at the follow-
up by phone at day 14.
Experiences and barriers to measuring planned outcomes of
the full RCT
We measured this outcome using a feedback form. We
only invited physicians and nurses who recruited pa-
tients or were involved in data collection for at least two
patients to provide feedback. We obtained feedback
from 15 ENT specialists (15/51; 29%), six GPs (6/9;
67%), 16 nurses (16/39; 41%), six pharmacists (6/35;
17%) and four audiologists (4/6; 67%).
Most ENT specialists and GPs rated obtaining consent
from parents, recruiting and stratifying patients into the
study, and using otoscopes as ‘easy’. The common obsta-
cles were (1) reluctance to participate due to the term
‘research’ in the consent form; (2) lengthy time to deliver
extensive study information; (3) time constraints due to
the need for an increased appointment length and pres-
sure of patient numbers; and (4) a complex eligibility
form. General practitioners found using an otoscope was
challenging in some patients due to the narrowness of
ear canals and uncooperative children. Most ENT spe-
cialists (73%) rated completing the CRFs as ‘easy’, whilst
most GPs rated this as ‘neutral’ (50%). The ENT special-
ists recommended simplification of the CRFs.
Most ENT specialists and GPs rated VAS (71% and
75%, respectively) and AOM-SOS (85% and 100%) as
‘easy’, although more information on pain description
was required. They suggested using a facial scale to
measure pain. They found AOM-SOS was suitable to
assess pain in young children.
Table 3 The adherence to the study
Adherence to the study Prednisolone
(n = 31)
Control
(n = 31)
Not compliant to the completion of symptom diary
No data after baseline for primary outcome
analysis
2 0
Data collected retrospectively by interview 4 13
Unclear responses clarified by interview 5 3
Not compliant to study medicationa
Missed one dose, but taken on the next day 1 –
Vomited constantly and stopped the study
medication
1 –
Took half of dose, vomited < 30 min
and took another half of dose
1 –
Took medicine in the afternoon (not in
the morning)
2 –
Not compliant to the follow-up visits
Delayed timing of follow-up visit 3 3
Left study 2 2
Additional interventions
Received additional oral corticosteroids 3b 1c
Received intervention of co-medication
from study investigator
2 5
aNine patients did not complete diary, but the adherence confirmed
by interview
bAt day 10, 12 and 60
cAt day 7
Table 2 Recruitment rates
Recruitment details according logbook Feb Mar Apr May Jun Jul Aug Sep Oct Nov Monthly mean
Recruitment ratea (%) 0 48 33.3 44.4 33.3 66.7 40 40 35.7 20.7 38.5
Screened children with AOM 1 25 18 9 6 15 15 15 28 29 16.1
Recruited to the study 0 12 6 4 2 10 6 6 10 6 6.2
Did not meet study criteria 0 7 4 2 2 4 7 8 14 21
Onset > 2 days 0 4 3 2 1 3 4 4 7 10
Prior antibiotic/steroid intake 0 3 1 0 0 1 1 2 4 8
Chronic/immunodeficiency disorders 0 0 0 0 0 0 2 0 0 0
Unable for follow-up visits 0 0 0 0 1 0 0 2 3 3
Declined to participate 1 5 6 3 1 1 0 1 4 1
Not offered participation 0 1 2 0 1 0 2 0 0 1
aRecruitment rate = children with AOM aged six month to 12 years who were recruited into the study divided by all children with AOM aged six months to 12
years who were being assessed for the study by participating physicians
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Most nurses rated the randomisation process and CRF
compilation, preparation and storing as ‘easy’, and rated
treatment allocation and prescription dispensing as ‘neu-
tral’. They found obstacles when accessing the random-
isation website due to complicated access steps and
unstable internet connection. They also found these
were time-consuming, particularly in terms of random-
isation and CRF compilation, which were not always
feasible due to workload. Most nurses contacted the 24-
h call centre for assistance in the randomisation and re-
cruitment process.
The pharmacists and audiologists rated the prepar-
ation and dispensing of study medication, and tympano-
metry examination as ‘very easy’ to ‘easy’. We also
obtained feedback from our research assistants (n = 6)
who conducted tympanometry examination in primary
care centre. Only one rated this as ‘difficult’ due to the
narrowness of ear canals.
We obtained feedback from parents regarding the
completion of the symptom diary (see Fig. 3). The ma-
jority of parents rated VAS (47%), AOM-SOS (71%) and
the completion of symptom diary (62%) as ‘easy’. Parents
preferred to use a numeric pain scale.
Adherence to study visits and study medication
Fifty-eight children completed all follow-up visits and
four children left the study (see Table 3). We visited
homes of those who were not able to come for their
follow-up visits. During this visit, we did not prescribe
any medication and recommended they visit the
hospital/primary care centre for any concerning condi-
tion (e.g. worsening AOM, complications).
Four children received additional oral corticosteroids:
one from a participating physician for AOM and three
children received it from other physicians for asthma,
prolonged cough due to allergy and sore throat. All re-
ceived this after measurement of the primary outcome
(see Table 3).
Interference by research investigator
Due to the lack of available second-line antibiotics and
other medications in primary care centres, the principal
investigator (RR), who was not blinded to the interven-
tion allocation, provided several medications to seven
patients: second-line antibiotics (4/62; 6%); ibuprofen (4/
62; 6%); combined decongestant-antihistamine (6/62;
10%); cough syrup (5/62; 8%); topical decongestant (4/
62; 6%); and nasal saline drops (1/62; 2%). More children
in the control group received interference, since most
children in primary care centres were randomly allo-
cated to this group by chance.
Verification of sample size calculation for the full RCT
Based on our original sample size calculation, we need
to enrol 760 children with AOM. We estimated, based
on data by Rovers et al. [38], that there would be 35% of
the total sample of children with AOM in the severe
group, of which 57.5% would have ongoing pain at day 3
in the control group. However, in our study, 78% of our
total sample was in the severe group with risk of
Fig. 3 Parents’ experience in measuring planned outcomes for the main study
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ongoing pain (≥ 5 mm VAS) at day 3 in control group of
42%. Of the children with mild AOM, 57% in the control
group had ongoing pain at day 3. The average propor-
tion of children with ongoing pain when combining the
mild and severe groups was 45.2%. With our original as-
sumption of 0.70 risk ratio with steroids, we will need to
study 201 experimental and 201 control subjects to be
able to reject the null hypothesis with probability
(power) 0.8 and type I error probability of 0.05. We will
use an uncorrected chi-squared statistic to evaluate this
null hypothesis. With a 10% allowance for dropouts, the
total sample size becomes 444.
There is a notable difference in the sample size estima-
tion between our original sample size and our pilot
study (see Table 4). The calculation of our original sam-
ple size was based on assumptions from a meta-analysis
of studies conducted in developed countries. Our up-
dated sample size using the pilot study results demon-
strated that we need a smaller sample size for the full
RCT if it is conducted in an urban setting in a develop-
ing country. The sample size may change if the study is
conducted in different settings or countries. We are
therefore presenting our assumptions for the sample size
calculation for a clinical trial conducted in different set-
tings (see Table 4).
Change of middle ear effusion
We found no difference in middle ear effusion (MEE)
change represented by SAA between the prednisolone
and control groups at day 3 (MD 0.04 mmho, 95% −
0.07 to 0.16), day 7 (MD 0.07 mmho, 95% − 0.06 to
0.19), day 30 (MD − 0.05 mmho, 95% − 0.19 to 0.09) and
day 90 (MD 0 mmho, 95% − 0.14 to 0.14). Consistent re-
sults were found after adjustment for the baseline results
(see Table 5). All differences were well below the mini-
mum clinical important difference of 0.3 mmho.
Duration of middle ear effusion
Although the confidence interval was very wide, there
was no difference in the proportion of children who had
complete resolution of MEE between the prednisolone
and control groups at day 3 (RR 1.76, 95% CI 0.65 to
4.73), day 7 (RR 1.47, 95% CI 0.71 to 3.04), day 30 (RR
1.07, 95% CI 0.57 to 2.00) and day 90 (RR 1.17, 95% CI
0.80 to 1.72). We also identified any improvement of
curve type from the baseline and previous results. Im-
provement was defined as an improvement from type B
curve to type C2, C1 or A curve; or from type C2 curve
to type C1 or A curve; or type C1 to A curve; or persist-
ing type A curve. Table 6 shows the tympanometry
curve improved compared to the baseline in more chil-
dren in the prednisolone group at day 7 (RR 1.76, 95%
CI 1.04 to 2.97).
Correlation between ear pain and other relevant symptoms
and the change of MEE
We expected there would be a strong negative correl-
ation between lower VAS (no or less pain) scores or
lower AOM-SOS scores (no or less AOM-relevant
symptoms) and higher values of SAA (no middle ear ef-
fusion), particularly at early timepoints. However, our
analysis demonstrated only a small correlation between
pain and other AOM-relevant symptoms and MEE at
day 3 and 7 (see Fig. 4), as well as later (day 30 and 90)
(see Additional file 1).
For clinical outcomes of this pilot study, we found that
prednisolone reduced pain severity at day 3 by 7 mm
(MD − 7.37, 95% CI − 13.36 to − 1.39, p = 0.018). Al-
though it was less than 10 mm (the minimum clinical
important difference), the CI included 10 mm which in-
dicates there may be a clinically important reduction in
pain severity. There was no statistically significant differ-
ence in the proportion of children with ongoing pain at
days 1, 3, 5, 7 and 14 (see Additional file 1). Neither was
there a difference between groups in reduction of pain
severity at these timepoints except day 3. The results
remained consistent after being adjusted for the baseline
pain score (ANCOVA).
Harm
Regarding harm or adverse events (AEs), there were
more children in the prednisolone group that
Table 4 Sample size assumptions for a clinical trial of corticosteroids for AOM conducted in different settings
Proportion of children Original assumption [38]a Middle scenario Pilot observed resultb
With severe AOM 35% 56% 78%
With severe AOM AND ongoing pain 57.5% 50% 42%
With mild AOM 65% 43% 22%
With mild AOM AND ongoing pain 36% 46% 57%
With severe and mild AOM AND ongoing pain 31.6% 38.4% 45.2%
Sample size calculationc 760 570 444
aFrom a meta-analysis of studies conducted in developed countries
bOur pilot study was conducted in a developing country, urban setting
cThe sample size includes a 10% allowance for dropouts
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experienced drowsiness (RR 1.77, 95% CI 1.11 to
2.81, p = 0.016) (Table 7). This can be translated as
for every three paediatric AOM patients who re-
ceived oral prednisolone, one additional patient ex-
perienced drowsiness (number needed to harm/
NNTH of 3). However, there were no serious AEs of
any kind attributed to study medication. There were
no significant differences in the proportion of chil-
dren experiencing other AEs between two groups,
including those AEs commonly attributed to short-
course oral corticosteroids use such as gastrointes-
tinal problems (e.g. nausea, vomiting, diarrhoea). We
found one child in the prednisolone group who had
microcytic hypochromic anemia at day 6 based on
low haemoglobin and serum iron counts. He was re-
ferred to a paediatrician who then confirmed this
was most likely caused by iron deficiency and not by
steroid intake.
Sensitivity analysis
Due to interference of the principal investigator who
was not blinded to study medication allocation, we con-
ducted a sensitivity analysis by excluding the children
who received interference. This did not change the
results.
Discussion
Our pilot study met our two key objectives related to
the feasibility of the full-size RCT and mechanistic effect
of corticosteroids on MEE. We found that less than 40%
of screened children were recruited. Most physicians
and parents rated study procedures as ‘neutral’ to ‘easy’.
However, most healthcare personnel found time con-
straints due to workload as their most common obstacle
in the study. The sample size needed to power a full ran-
domised controlled trial is lower than anticipated. Most
children completed the study (97%), and a minority
Table 5 Static acoustic admittance values in the affected (unilateral AOM) or the worst ear (bilateral AOM)
Static acoustic admittance:
mmho mean ± SD
Prednisolone
(n = 15)
Control
(n = 22)
Unadjusted mean
difference
p value Adjusted mean
differencea
p value
Day 0 (visit 1) 0.19 ± 0.13 0.24 ± 0.22 − 0.05 (− 0.18, 0.08)
Day 3 (visit 1) 0.26 ± 0.15 0.22 ± 0.17 0.04 (− 0.07, 0.16) 0.43 0.07 (− 0.02, 0.16) 0.13
Day 7 (visit 2) 0.32 ± 0.15 0.25 ± 0.20 0.07 (− 0.06, 0.19) 0.08 (− 0.03, 0.20)
Day 30 (visit 3) 0.32 ± 0.18 0.37 ± 0.22 − 0.05 (− 0.19, 0.09) − 0.03 (− 0.16, 0.10)
Day 90 (visit 4) 0.41 ± 0.18 0.41 ± 0.22 0 (− 0.14, 0.14) 0.02 (− 0.11, 0.16)
aAdjusted for the baseline static acoustic admittance value
Table 6 Tympanometry finding in the affected (unilateral AOM) or the worst ear (bilateral AOM)
Tympanometry findings Prednisolone (n = 15) Control (n = 22) Effect estimate (relative risk) p value
Complete middle ear effusion resolutiona (n, %)
Day 3 (visit 1) 6 (40) 5 (23) 1.76 (0.65, 4.73) 0.29
Day 7 (visit 2) 8 (53) 8 (36) 1.47 (0.71, 3.04)
Day 30 (visit 3) 8 (53) 11(50) 1.07 (0.57, 2.00)
Day 90 (visit 4) 12 (80) 15 (68) 1.17 (0.80, 1.72)
Improvement of curve type from baseline visitb (n, %)
Day 3 (visit 1) 7 (47) 7 (32) 1.47 (0.65, 3.32) 0.49
Day 7 (visit 2) 12 (80) 10 (45) 1.76 (1.04, 2.97)
Day 30 (visit 3) 10 (67) 14 (64) 1.05 (0.65, 1.69)
Day 90 (visit 4) 14 (93) 16 (73) 1.28 (0.96, 1.71)
Improvement of curve type from previous visitc (n, %)
Day 3 (visit 1) 7 (47) 7 (32) 1.47 (0.65, 3.32) 0.49
Day 7 (visit 2) 9 (60) 9 (41) 1.47 (0.76, 2.81)
Day 30 (visit 3) 9 (60) 13 (59) 1.01 (0.59, 1.74)
Day 90 (visit 4) 13 (87) 15 (68) 1.27 (0.89, 1.80)
aComplete resolution is defined as a type A curve in tympanometry examination
bImprovement of curve type is defined as an improvement from type B curve to type C2, C1, or A curve; or from type C2 curve to type C1 or A curve; or type C1
to A curve; or persisting type A curve at particular time point compared to the baseline
cImprovement of curve type is defined as an improvement from type B curve to type C2, C1, or A curve; or from type C2 curve to type C1 or A curve; or type C1
to A curve; or persisting type A curve at particular time point compared to the previous visit
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Fig. 4 Correlation between pain or AOM-relevant symptoms and change in middle ear effusion
Table 7 Adverse events in the study
Adverse events Prednisolone group (n = 31) Control (n = 31)
No ptsa Day 1–3 Day 4–7 Day 8–14 No ptsa Day 1–3 Day 4–7 Day 8–14
Increased appetite 18 11 15 17 17 9 10 7
Increased urine volume 11 8 9 7 14 12 7 4
Weight gain 13 5 6 6 11 4 4 10
Gastritis 2 3 2 0 4 2 0 0
Nausea 6 4 1 0 7 5 4 1
Vomiting 5 3 0 0 3 3 1 1
Diarrhoea 2 3 1 1 4 1 0 0
Drowsiness 23 14 9 6 13 16 10 5
Anxiety 4 3 3 3 6 3 1 1
Headache 4 1 0 1 6 7 2 3
Skin rash 3 0 1 0 0 2 0 0
Candidiasis 3 2 1 0 1 1 0 0
Dry mouth 7 5 4 0 6 6 3 1
Sleep disturbance 17 5 5 3 10 9 1 0
Others 1 0b 1 0 0 0 0 0
Serious adverse effects 0 0 0 0 0 0 0 0
aTotal number of patients having the adverse event during the first 2 weeks
bPatient was detected to have anemia at day 6 (no baseline Hb count was identified) at the primary care centre and was referred to paediatrician
Pts patients
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received concomitant oral corticosteroids and other co-
treatments from an unblinded researcher. There is the
potential that corticosteroids may reduce pain severity at
day 3 and improve tympanometry curve by day 7. We
found only a small correlation between the change in
MEE and pain and other AOM-relevant symptoms. We
also found drowsiness as the most common side effect
of oral corticosteroid.
There were several limitations of this pilot study. Our
recruitment rate was low and similar (38.5%) to other
studies conducted in developing countries [39]. This
could be because we started recruiting at hospital cen-
tres, but well-implemented national coverage insurance
required patients to access healthcare services via pri-
mary care centres. It could also be due to (1) low re-
search awareness/interest among physicians, nurses and
patients [40]; (2) workload of physicians and nurses; (3)
cultural factors (e.g. patients seeking family/relatives’
consent to participate in research); and (4) insufficient
clinical trial facilities [40]. To improve recruitment, fu-
ture studies could (1) recruit from more primary care
centres; (2) provide incentives for participating health-
care personnel despite insufficient evidence of effects on
recruitment rate [41]; and (3) simplify the study process
(simplifying and improving the layout of CRFs and
symptom diary and allocating research assistants to sup-
port study procedures including randomisation).
We could not provide a matched placebo control. Par-
ents’ subjective responses to pain assessment could have
been biased by this, as they knew which treatment their
child received. However, we plan to use a placebo in the
full RCT where we will involve an independent specia-
lised drug manufacturer to provide a placebo that is
similar in form and taste with oral prednisolone.
Four children received additional oral corticosteroids.
Although we asked parents to contact us before they
sought consultation from other physicians for any rele-
vant or other concurrent conditions, this was not suffi-
ciently implemented. Therefore, for the full RCT, we will
provide a handy information card that provides detailed
information about the study, including medication that
should not be given. This card should be shown to any
physicians that the parent consults.
Imbalanced randomisation meant that there were
more children in the control group who had low paren-
tal education level, were exposed to parental smoking
and received amoxicillin and acetaminophen compared
to those in the prednisolone group. One potential con-
tributing factor was that, by chance, most children in the
control group were recruited from the primary care cen-
tres. Out of 31 children in the control group, 13 were re-
cruited from the primary care centres (55%) and out of
31 children in the prednisolone group, only six were re-
cruited from primary care centres (19%). Low parental
education level may be associated with higher rates of
passive smoking in the control group. This was sup-
ported by evidence showing education attainment and
length of education negatively correlated with smoking
behaviour [42]. Parental smoking has been identified as
a strong risk factor for AOM [43–45]. First line antibi-
otics for AOM and analgesics in primary care centres in
Indonesia are amoxicillin and acetaminophen [15]. This
is consistent with the antibiotic recommended for AOM
in guidelines, but at a lower dose (50 mg/kg body
weight/day) [15]. This chance imbalance in randomisa-
tion will likely be reduced by stratification on the type of
healthcare facility (primary versus secondary/tertiary
care centre).
The last limitation was missing tympanometry values,
which was caused by the inability of tympanometry to
detect key values (i.e. SAA, middle ear pressure) in some
severe cases of MEE. However, this problem was de-
tected after several incomplete test values which resulted
in missing data from several cases. Despite this, given
the lack of clinical benefit of this examination in AOM
cases, the need of specific skills and facilities, and cost,
we do not intend to include the tympanometry measure-
ment in the full RCT.
We also found positive impacts of this study. The first
strength of this study is its ability to identify potential is-
sues particularly in the recruitment and data collection
which allows us to modify study procedures and strat-
egies for a successful implementation of the full RCT
[46]. Secondly, we also believe this pilot study has intro-
duced a clinical trial to healthcare personnel at several
levels of healthcare service in Indonesia. We expect this
will trigger their interest in research since they now have
some knowledge and experience in conducting a clinical
trial.
Our original primary outcome was the proportion of
children with ongoing pain that has not reduced by the
minimum clinically important amount (VAS score of 10
mm) by day 3. However, our pilot study demonstrated
that the majority of the children had their pain signifi-
cantly improved at day 3. Therefore, we will change the
primary outcome in the main RCT to be the proportion
of children with persisting pain (defined as the VAS
score greater than 5 mm). We will retain the secondary
outcome, that is the reduction of pain intensity using
VAS, which will allow us to identify the effectiveness of
oral prednisolone to improve pain by the previously-
defined minimum clinically important amount.
As we included different levels of healthcare service
in several districts in Jakarta in the pilot study, we
are confident that it is feasible to conduct the full
RCT in other cities in Indonesia, particularly on Java.
Training prior to the trial customised to education
level of healthcare personnel is crucial. The
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availability of an otoscope will be a potential limita-
tion for a large-scale RCT.
This study also showed that the incidence of severe
AOM (47/62; 76%) was higher compared to other trials
referenced in this study that were mainly conducted in
developed countries. If a large RCT is conducted in
Indonesia or other developing countries with similar
AOM characteristics, then it will predominantly evaluate
the effects of oral corticosteroids as an addition to
antibiotics.
Decongestants and/or antihistamines were com-
monly prescribed at baseline consultation. Most AOM
patients experienced symptoms of the common cold
which could explain this finding. Evidence shows that
the combination of decongestants and antihistamine
is beneficial for general recovery in adults and older
children with common cold, but not in young chil-
dren (age < 5 years) [47]. Regarding its effects for
AOM, decongestants and/or antihistamines have only
a modest benefit in reducing the risk of persistent
AOM in 2 weeks with significant adverse events over-
weighting the benefits [19].
We re-introduced the use of pain assessment tools
(i.e., VAS and AOM-SOS) which have not been rou-
tinely used in the management of children with AOM in
our clinical setting. Most parents assessed their chil-
dren’s pain by observation. Only few older children (5/
62; 6%) did a self-rated pain assessment.
We also found that most parents and physicians
preferred to use a numeric or facial pain scale. One
of the commonly used self-report numeric scales for
acute pain is the 11-point Numeric Rating Scale
(NRS-11). Children, particularly aged 6 years and
older, determine their pain intensity by choosing a
number between 0 (representing ‘no hurt’) and 10
(representing ‘the worst hurt’) scale [48, 49]. For fa-
cial pain scale, a Faces Pain Scale-Revised (FPS-R)
was recommended as a self-report acute pain scale
for children aged 7 years and older. It consists of six
faces ranging from ‘no pain’ to ‘very much pain’,
where each face was represented by numbers of 0-2-
4-6-8-10 [48, 50]. However, since there was no strong
evidence supporting the recommendation of any par-
ticular parent-report pain assessment for paediatric
population with acute pain, we still consider it appro-
priate to use VAS and AOM-SOS for the full RCT.
This pilot study also verified that these pain assess-
ment tools were successfully implemented by the par-
ents in assessing pain.
We did not find clinically significant benefits of tym-
panometry examination for the management of AOM. It
was costly and difficult to implement in children experi-
encing pain. Evidence demonstrates that only certain
children may be at risk of prolonged MEE resolution
(children with AOM aged < 2 years or, children with re-
current AOM). Therefore, tympanometry examination
should be prioritized for those children and not to be
generalised for all AOM cases [9, 51]. We will further in-
vestigate any prognostic factors and characteristics of
our study participants in the tympanometry sub-study
that may influence the improvement or prolongation of
MEE.
We found drowsiness as the most common side effect
of oral corticosteroid, which is consistent with AEs re-
lated to a short-term use of oral corticosteroids in other
studies [21, 26]. However, this requires further investi-
gation since more children in the prednisolone group
received decongestants and/or antihistamines, and
drowsiness has been identified as common side effect of
decongestants and/or antihistamines with risk up to
eight-fold of risk in the treatment group [19, 52, 53].
Compared to other feasibility interventional studies,
our pilot study had similar recruitment issues which re-
quired additional recruitment time and modification of
the recruitment strategy [54]. Our study had a lower re-
cruitment rate compared to other feasibility studies [55].
However, like other studies, our pilot study had a low
rate of incomplete outcome data (6%) [54].
Conclusions
Our pilot study shows that it is feasible to conduct a
large, pragmatic, randomised, double-blind placebo-
controlled trial. However, several modifications should
be made to improve feasibility: simplifying study pro-
cedures, improving the layout of CRF and symptom
diary, recruiting through primary care centres, strati-
fying children based on severity and healthcare centre
level and the use of placebo as a control. We will use
VAS and AOM-SOS as pain assessment tools since
there is no strong evidence recommending a particu-
lar parent-report assessment tool for children with
acute pain. The sample size required is less than we
anticipated due to the high proportion of severe
AOM cases, and it is not necessary to use tympano-
metry for a future trial. Based on the findings and re-
sults from this pilot study, we modified our protocol
for the full RCT (see Additional file 2).
Our clinical results do not rule out the benefit of oral
corticosteroids for AOM. However, the signal of its ben-
efits is small. We also identified drowsiness as one side
effect of a short-term us of oral corticosteroids, with no
excess of other AEs commonly attributed to short-
course oral corticosteroids use (i.e. nausea, vomiting,
diarrhoea) found. Therefore, our pilot study confirms
the importance of conducting our planned full RCT to
assess the actual effects, both benefits and harm, of oral
corticosteroids for children with AOM.
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